Last reviewed · How we verify
MCI-186
MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue.
MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue. Used for Acute ischemic stroke, Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | MCI-186 |
|---|---|
| Also known as | Edaravone, Radicut, Radicava |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Free radical scavenger; antioxidant |
| Target | Reactive oxygen species (ROS); hydroxyl radicals; peroxynitrite |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
MCI-186 (edaravone) acts as a potent antioxidant by scavenging free radicals, particularly hydroxyl radicals and peroxynitrite, which are implicated in neuronal damage. By reducing oxidative stress and subsequent neuroinflammation, it may limit the progression of neurodegeneration in acute ischemic stroke and amyotrophic lateral sclerosis (ALS). The drug crosses the blood-brain barrier and exerts neuroprotective effects during the acute phase of injury.
Approved indications
- Acute ischemic stroke
- Amyotrophic lateral sclerosis (ALS)
Common side effects
- Injection site reactions
- Headache
- Nausea
- Dizziness
- Hypersensitivity reactions
Key clinical trials
- A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects (PHASE1)
- Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids (PHASE2)
- Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study (PHASE4)
- Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment (PHASE1)
- PK Study in Subjects With Severe Hepatic Impairment (PHASE1)
- Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke (PHASE2)
- Dose Finding Study of MCI-186 in Acute Ischemic Stroke (PHASE2)
- Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCI-186 CI brief — competitive landscape report
- MCI-186 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI